Travere Therapeutics (TVTX) Tops Q2 EPS by 16c
Tweet
Share
E-mailGet Alerts TVTX Hot Sheet
Join SI Premium – FREE
Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($0.14), $0.16 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $114.4 million versus the consensus estimate of $99.25 million.
For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Boeing lands two U.S. defense contracts worth over $711M
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
